Can You Overdose on Psilocybin Mushrooms?

A fatal overdose from psilocybin mushrooms alone is extraordinarily rare, and the lethal dose in humans would require consuming a quantity so far beyond any recreational or therapeutic amount that it borders on physically impossible. Animal studies put the lethal threshold at hundreds of milligrams per kilogram of body weight, while a strong human dose is only about 30 to 40 milligrams total. But “you probably won’t die” and “it’s safe” are not the same statement. Psilocybin carries genuine physical risks at high doses, can trigger psychiatric emergencies in vulnerable people, and the behavioral effects of a severe experience can be life-threatening even when the drug itself isn’t.

What a Lethal Dose Would Actually Look Like

The standard way toxicologists gauge how deadly a substance is involves the LD50, the dose that kills half the animals in a controlled experiment. For psilocybin, those numbers are remarkably high. In mice, the LD50 was established at 275 mg/kg intravenously and 420 mg/kg when injected into the abdomen. In rats it was similar, around 280 mg/kg intravenously. Rabbits turned out to be the most sensitive species tested, with an LD50 of just 13 mg/kg intravenously.¹ No controlled lethal-dose study exists in humans, for obvious ethical reasons. But extrapolating loosely from the animal data, a person would likely need to ingest many grams of pure psilocybin to approach a fatal threshold. A strong dose of dried Psilocybe cubensis mushrooms contains roughly 10 to 30 mg of psilocybin, which means someone would need to eat an absurd quantity of mushrooms in a single sitting. This is one reason confirmed deaths from psilocybin toxicity alone are essentially absent from the medical literature.

What High Doses Actually Do to the Body

Even though psilocybin won’t kill you through direct toxicity at any plausible dose, it isn’t gentle on the cardiovascular system. A safety study that tracked 113 psilocybin administrations in healthy volunteers at doses ranging from 15 to 30 mg found that half of all sessions produced systolic blood pressure above 140 mmHg, and about 6 percent pushed it above 160 mmHg. No one hit severe hypertension above 180 mmHg. Heart rate stayed mostly normal; only about 7 percent of sessions produced a peak heart rate above 100 beats per minute. Body temperature rose in a dose-dependent way, exceeding 38°C in roughly a third of the 30 mg sessions and 7 percent of the 15 mg sessions. The highest recorded temperature was 39°C, and nobody developed dangerous hyperthermia above 40°C.² A head-to-head comparison with LSD found that 30 mg psilocybin actually pushed blood pressure and body temperature higher than LSD did, though LSD produced a greater increase in heart rate.³

For a young, healthy person, a temporary blood-pressure spike to 160 mmHg is uncomfortable but not catastrophic. For someone with uncontrolled hypertension, a preexisting heart condition, or cerebrovascular risk, those numbers are more concerning. This is why clinical trials routinely screen out participants with cardiovascular problems, and why unmonitored high-dose use carries more risk for people who don’t know their cardiac baseline.

A systematic review and meta-analysis of adverse effects at therapeutic doses confirmed that psilocybin roughly doubled the risk of headache and elevated blood pressure compared to placebo, with nausea being the most dramatically elevated side effect at nearly nine times the risk of control conditions. Anxiety and dizziness were also significantly more common. Headache appeared in anywhere from 2 to 66 percent of participants across the pooled studies, and nausea in 4 to 48 percent.⁴ A separate systematic review of psilocybin-assisted psychotherapy found the same common side effects, including elevated blood pressure, headaches, nausea, vomiting, fatigue, and anxiety, and noted that suicidal ideation appeared infrequently and mainly in participants who already had a history of suicidal thoughts.⁵

Heart Valve Concerns and Repeated Use

One fear you’ll encounter online is whether psilocybin could damage heart valves, the way the withdrawn diet drug fenfluramine did. Both substances act on the 5-HT2B serotonin receptor, which is implicated in the kind of tissue growth that leads to valvular heart disease. But a recent exposure-response model found that psilocin, the active metabolite of psilocybin, activates that receptor at only about half the maximum intensity of serotonin itself, compared to 96 percent for norfenfluramine and 62 percent for LSD. Because psilocin acts as a partial agonist, it physically cannot drive the receptor signal beyond roughly half of what a full agonist can, no matter how much you take.⁶ This doesn’t make the question permanently settled, especially for people microdosing daily over months or years, but the pharmacological safety margin is substantially wider than the fenfluramine comparison would suggest.

The Real Emergency Room Story

If psilocybin rarely causes lethal toxicity, you might wonder why people end up in the ER after taking mushrooms. The answer is mostly psychological, not medical. A large survey of past-year magic mushroom users found that only 0.2 percent sought emergency medical treatment, translating to a per-event risk of about 0.06 percent. The most common symptoms driving those visits were anxiety, panic, and paranoia. Poor mindset going in, a bad environment, and mixing substances were the top reasons incidents happened. Almost everyone returned to normal within 24 hours.⁷

A broader analysis of U.S. poison center data between 2000 and 2016 captured nearly 5,900 psilocybin mushroom exposures. The most common effects reported were hallucinations, agitation, and elevated heart rate. Serious clinical effects did occur but were infrequent, including hyperthermia, seizures, coma, and in rare cases cardiac arrest. Most patients were treated and released from the emergency department, and fewer mushroom patients needed critical care admission compared to LSD patients.⁸

The Psychological Risks Are the Serious Ones

The most dangerous aspect of a high psilocybin dose is often what happens in your mind, and what you do in response. A survey of nearly 2,000 people about their worst “bad trip” on psilocybin mushrooms found that 39 percent rated it among the top five most challenging experiences of their lives. About 11 percent put themselves or others at risk of physical harm during the experience, with the likelihood climbing as dose, duration, and difficulty of the trip increased and as physical comfort and social support decreased. Roughly 2.6 percent became physically aggressive, and 2.7 percent sought medical attention. Among people whose experience happened more than a year before the survey, 7.6 percent later sought treatment for lasting psychological symptoms. Three cases were linked to the onset of enduring psychotic symptoms and three to attempted suicide.⁹

The hallmark of a bad trip is a feeling of losing yourself or going insane, sometimes described in the clinical literature as ego dissolution.¹⁰ This can spiral into intense fear, anxiety, and the surfacing of unresolved trauma.¹¹ For some people this is merely unpleasant; for others it leads to dangerous behavior. One published case involved a young man with no psychiatric history who jumped from a second-story balcony while under the influence of psilocybin mushrooms, highlighting that impaired judgment during a trip can be fatal even when the drug itself isn’t.¹²

Who Faces Higher Risk

Not everyone sits at the same baseline of psychological safety. People with predisposing psychiatric factors face a distinct set of dangers that healthy users don’t. A case report of a patient with a history of depression and personality disorder traits documented a psychotic episode with catatonic features and suicidal behavior after several months of heavy psilocybin use. A review of similar published cases found a clear pattern: psilocybin-induced psychosis occurs mainly in people with pre-existing vulnerability who consume high or repeated doses.¹³

Bipolar disorder is a particularly important risk factor. A large web-based survey of people with bipolar disorder who had used psilocybin found that about a third reported new or worsening symptoms after trips, with manic symptoms being the most common at about 14 percent, followed by sleep difficulties and anxiety.¹⁴ Meanwhile, a study of adolescent psychedelic use found that genetic vulnerability to schizophrenia or bipolar I disorder significantly amplified the association between psychedelic use and manic symptoms.¹⁵ This is why virtually every clinical trial excludes participants with psychotic spectrum disorders or bipolar disorder, and why the phrase “set and setting” extends beyond ambiance to include knowing your own psychiatric history.

Serotonin Syndrome and Drug Interactions

One plausible route to a dangerous medical event from psilocybin involves not the mushrooms alone but their combination with other drugs, particularly anything that boosts serotonin. Serotonin toxicity, sometimes called serotonin syndrome, typically occurs when a drug that increases serotonin in the brain is combined with a monoamine oxidase inhibitor. A review of serotonin toxicity cases and psychedelics concluded that serotonergic drugs that do not contain MAOIs are low risk when combined with psychedelics that also do not contain MAOIs.¹⁶ The practical concern here is that some people combine psilocybin with ayahuasca-related brews, Syrian rue, or pharmaceutical MAOIs, either unknowingly or intentionally to intensify the trip. That combination changes the risk calculus entirely. If you are taking any psychiatric medication, the interaction question is worth serious attention before consuming psilocybin.

Why Tolerance Builds So Quickly

One feature of psilocybin that somewhat limits the risk of escalating overdose is how fast the body builds resistance to it. Repeated administration within a short period leads to a rapid accumulation of tolerance to psilocybin’s effects, and this tolerance extends across other classical psychedelics like LSD and mescaline as well.¹⁷ In practical terms, taking mushrooms two days in a row produces a dramatically weaker experience the second day. This built-in brake means psilocybin doesn’t lend itself to the kind of compulsive redosing that drives overdose patterns with opioids or stimulants. It doesn’t eliminate the risk of someone taking a very high dose at once, but it makes an escalating binge over several days less likely to produce increasingly dangerous effects.

Accidental Exposures and Children

With psilocybin products increasingly available in chocolate bars and gummy forms, accidental pediatric exposures have become a growing concern. A case series of psychedelic mushroom-containing chocolate exposures found a median patient age of 17, with most cases being intentional. Common effects included mental status changes, paranoia and hallucinations, irregular heart rhythms, and gastrointestinal discomfort. One seizure was reported. Most effects resolved within 3 to 24 hours, and no fatalities occurred. Intravenous fluids and benzodiazepines were the treatments most commonly given.¹⁸

For younger children, the broader picture of accidental mushroom ingestion is reassuring in most cases. An analysis of over 50,000 unintentional pediatric mushroom exposures reported to U.S. poison centers between 2009 and 2023 found that the vast majority (about 89 percent) produced no symptoms at all, and 80 percent were managed at home. Minor effects occurred in 5 percent of cases, moderate effects in 0.6 percent, and major effects in just 0.03 percent.¹⁹ That data covers all mushroom types, not just psilocybin-containing species, but it gives a useful baseline: small accidental ingestions in children very rarely lead to serious medical outcomes.

What Else Is in the Mushroom

Psilocybin is the headline compound, but Psilocybe mushrooms contain a handful of related tryptamines, including baeocystin, norbaeocystin, and aeruginascin. Whether these meaningfully alter the experience or the safety profile is still being worked out. In mouse studies, only the tertiary amines, a chemical category that includes psilocybin and psilocin, produced head-twitch responses, the standard lab marker for psychedelic-like activity. The secondary amines like baeocystin did not.²⁰ A separate study in rats confirmed that only psilocybin induced head-twitch responses among the compounds tested. However, norbaeocystin did cross a blood-brain barrier model at a similar rate to psilocin and showed similar activity at the serotonin receptor believed to drive psychedelic effects. All compounds tested had minimal effects on kidney and liver health markers.²¹

The practical takeaway is that whole mushrooms are not identical to pure synthetic psilocybin, but the accessory compounds don’t appear to dramatically change the toxicity picture. What they might do to the subjective experience remains an open question. Products tested under quality-control frameworks, like standardized Psilocybe cubensis biomass, have been found to have acceptable levels of microbial contamination, mycotoxins, pesticides, and heavy metals, with no significant carcinogenic or other health hazards detected.²²

Flashbacks and Lasting Perceptual Changes

Some people worry about hallucinogen persisting perception disorder, a condition in which visual disturbances like halos, trails, or flickering continue long after the drug has left the system. It’s recognized as a real diagnosis. One published case involved an 18-year-old who developed perceptual disturbances lasting more than eight months after a combined psilocybin and cannabis experience.²³ But it appears to be quite rare. A pooled analysis of 142 healthy participants who received LSD or psilocybin in controlled settings found zero cases meeting the diagnostic criteria. Statistical modeling based on that sample suggested the true incidence is likely below 1 to 2 percent in healthy individuals given moderate doses under supervised conditions.²⁴ Whether the risk is higher in unsupervised settings, at higher doses, or with repeated use is harder to pin down.

How Regulated Settings Change the Picture

Oregon became the first U.S. state to create a legal, regulated framework for psilocybin services, and early data from that program offers a glimpse of what supervised use looks like at scale. Licensed manufacturers produce Psilocybe cubensis products that are laboratory-tested for both active compound content and contaminants. Clients self-administer on site under the supervision of a licensed facilitator, with a maximum allowable dose of 50 mg per session and no take-home doses. Among participants tracked in the program, roughly 44 percent were psychedelic-naive, and the average dose was about 32 mg. Facilitators or clients reported serious behavioral adverse reactions in just over 1 percent of sessions, four out of 346, with only one requiring medical attention. No serious medical adverse reactions were reported. All four of the serious behavioral reactions occurred in psychedelic-naive individuals who sought psilocybin for mental health symptoms.²⁵ That is a small dataset and a self-selected population, but the pattern is consistent with the broader literature: when dose is known, the setting is safe, and support is available, serious harm is uncommon.

Where Psilocybin Sits Among Other Drugs

Drug-harm rankings consistently place psilocybin at or near the bottom of the scale. In one survey of experienced drug users asked to assess the relative harms of various substances, alcohol and tobacco ranked as the most harmful, while psilocybin, LSD, and MDMA were rated as the least harmful.²⁶ A panel of German addiction medicine experts placed psychotropic mushrooms in the midrange of harm, alongside cannabis, LSD, and ketamine, and below alcohol, heroin, and methamphetamine.²⁷ These rankings capture overall harm, factoring in dependence potential, social damage, and physical toxicity. By every measure of direct physical lethality, psilocybin sits at the lowest end of the scale. The substances most commonly involved in fatal overdoses, opioids, benzodiazepines, alcohol, and stimulants, all have far narrower margins between a recreational dose and a deadly one.

That gap is the core answer to the overdose question. Psilocybin’s therapeutic index, the ratio between an effective dose and a lethal one, is enormous. You could take a dose many times stronger than intended and survive the physical effects. What you might not survive is the decision to climb onto a balcony railing during a panic, or the psychotic break that a trip triggers in someone with an undiagnosed vulnerability. The drug’s safety profile is genuinely unusual among psychoactive substances. The risks that remain are real, but they are mostly psychological and behavioral, not toxicological.